AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol (October 10, 2002). doi:10.1152/ajpheart.00563.2002
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/4/H1134    most recent
00563.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reffelmann, T.
Right arrow Articles by Kloner, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reffelmann, T.
Right arrow Articles by Kloner, R. A.

Articles in PresS, published online ahead of print October 10, 2002
Am J Physiol Heart Circ Physiol, 10.1152/ajpheart.00563.2002
Submitted on July 8, 2002
Accepted on October 4, 2002

Is Microvascular Protection by Cariporide And Ischemic Preconditioning Causally Linked to Myocardial Salvage?

Thorsten Reffelmann1* and Robert A. Kloner1

1 University of Southern California, The Heart Institute, Good Samaritan Hospital, Los Angeles, CA, USA

* To whom correspondence should be addressed. E-mail: ThorstenReffelmann{at}web.de.

Two independent cardioprotective interventions, Na+/H+-exchange inhibition and ischemic preconditioning (PC), were investigated with respect to differential effects on microvascular and myocardial salvage in anesthetized rabbits (30 minutes ischemia, 180 minutes reperfusion). 300 µg/kg cariporide before occlusion and PC reduced infarct size (IS, triphenyltetrazolium) (control: 46.0±4.2% of RA (risk area), cariporide: 17.6±3.7% (p<0.01), PC: 27.5±4.1% (p<0.01)), and concomitantly anatomic no-reflow (ANR, thioflavin S) (control: 40.4±3.7%, cariporide: 19.0±2.9% (p<0.01), PC: 26.9±3.4% (p<0.05)). Regional myocardial blood flow (RMBF, radioactive microspheres) in the RA, deteriorating between 30 and 180 minutes of reperfusion (control: 79±6% to 26±2% of non-ischemic flow), was shifted to higher values with both treatments (Cariporide: 110±12% to 49±7%, p<0.05, PC: 109±8% to 38±6%, p<0.05). However, neither intervention uncoupled the close relationship between IS and ANR (r=0.92-0.95) or RMBF. Cariporide given at reperfusion, did not alter IS, ANR, RMBF, or their close interrelationships. Since size and spatial distribution of no-reflow and myocardial necrosis remained closely coupled with independent cardioprotective interventions, a potential causal connection between microvascular and myocardial salvage is discussed.




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. L. Hale, A. Mehra, J. Leeka, and R. A. Kloner
Postconditioning fails to improve no reflow or alter infarct size in an open-chest rabbit model of myocardial ischemia-reperfusion
Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H421 - H425.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. Lerman, D. R. Holmes, J. Herrmann, and B. J. Gersh
Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence, or both?
Eur. Heart J., April 1, 2007; 28(7): 788 - 797.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G. J. Wilson and R. J. Diaz
The myocardial no-reflow phenomenon: Role of {delta}PKC
Cardiovasc Res, March 1, 2007; 73(4): 623 - 625.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. A. Kloner and S. H. Rezkalla
Cardiac protection during acute myocardial infarction: Where do we stand in 2004?
J. Am. Coll. Cardiol., July 21, 2004; 44(2): 276 - 286.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
T. Reffemann and R. A. Kloner
Microvascular Alterations After Temporary Coronary Artery Occlusion: The No-Reflow Phenomenon
Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 163 - 172.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
R. A. Kloner and W. Dai
Glycoprotein IIb/IIIa inhibitors and no-reflow
J. Am. Coll. Cardiol., January 21, 2004; 43(2): 284 - 286.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. Reffelmann and R. A Kloner
Cardiovascular effects of sildenafil in experimental ischemia-reperfusion (reply to "Sildenafil-induced cardioprotection in rabbits, by Kukreja, R.C., Ockaili, R., Salloum, F., Xi, L.")
Cardiovasc Res, December 1, 2003; 60(3): 702 - 703.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1976 by the American Physiological Society.